An Oxford-born AI company that spots hidden heart disease in routine echocardiogram scans. Its EchoGo tools help clinicians find heart failure and amyloidosis earlier.
Ultromics is an AI company that detects cardiovascular disease from routine echocardiograms, the ultrasound scans of the heart. Its stated mission is to help clinicians find hidden disease signals in routine scans so that patients can be identified earlier and get the right care. Its first focus is heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis.
The company began at the University of Oxford. Founder and CEO Ross Upton worked with Professor Paul Leeson, now the company's chief medical officer and a founder, on AI that identifies disease directly from echo images, not just automating measurements. That research became the basis for its EchoGo products.
Its products are EchoGo Heart Failure, EchoGo Amyloidosis and a platform that brings them together. Ultromics says its AI is deployed across leading US hospitals, and it names Dr Patricia Pellikka of the Mayo Clinic as a collaborator. Its news pages also report an NHSX grant to implement EchoGo in the NHS.
The pages we read do not state where Ultromics is headquartered, so we have not stated a location. They do show that it is a UK-founded health-AI company with a team of AI, clinical and commercial leaders.
For young people, Ultromics is a clear example of AI helping doctors rather than replacing them. Careers include machine learning, software engineering, clinical science, regulatory affairs and commercial roles. Medical and engineering students may find the company's research-to-product story helpful. Check its careers page for current roles; early-careers programmes are not described. We have left out funding.
Website: www.ultromics.com
PURPOSE helps school and university students explore 62 sectors and over 1,000 entry-level careers in the UK, then connects them directly with employers.
Explore PURPOSE